Table 1.

Characteristics of the subjects, the pharmacokinetic variables for rofecoxib, and the results of the caffeine test

				Rofecoxib			Caffeine/paraxanthine ratio
Subject number	Age, years	Weight, kg	Cmax, ng ml−1	AUC0–25, ng h ml−1	AUC0–∞, ng h ml−1	t1/2, h	During placebo (control)	During rofecoxib
2	21	84	367	5453	8846	9.1	1.66	3.74
3	22	80	243	3271	4332	10.9	0.89	1.58
4	21	83	196	2905	4347	14.4	0.91	2.37
5	22	80	320	4043	6700	18.2	1.26	3.58
6	21	73	302	3906	5374	12.3	1.45	2.78
7	23	71	324	4396	7929	20.9	1.75	7.66
8	25	87	331	5885	18818	40.0	3.26	7.79
9	20	64	407	4891	9648	24.6	1.32	1.81
10	22	86	241	3949	12490	44.2	1.66	2.38
Mean	22	79	303	4300	8721	21.6	1.57	3.74*
SD	1	6	66	971	4628	12.7	0.70	2.37

AUC_0–25, Area under plasma concentration–time curve from time 0–25 h; AUC_0–∞, area under plasma concentration–time curve from time 0 to infinity; C_max, maximum plasma concentration; t_1/2, half-life.

^*P = 0.008, vs. control.